120 likes | 199 Views
India. How to Access a Promising Market? Challenges from the Viewpoint of an Entrepreneur Interested to Access the Indian Market. Norbert Gerbsch, PhD Head of Affairs – Biotechnology / R&D BPI - German Pharmaceutical Industry Association. Population: 2006: 1.15 bn. 2030: 1.51 bn.
E N D
India How to Access a Promising Market?Challenges from the Viewpoint of an EntrepreneurInterested to Access the Indian Market Norbert Gerbsch, PhD Head of Affairs – Biotechnology / R&D BPI - German Pharmaceutical Industry Association
Population: 2006: 1.15 bn. 2030: 1.51 bn. a huge market! Growth Rates: 2008: 8.2% Above world average growing income! Drug Sales: Above par for three years growing sales! India – First Sight A Promising Market… Charts from: Deutsche Bank Research: India´s pharmaceutical industry on course for globalisation April 2008, www.dbresearch .com
India – First Sight Chart from: Deutsche Bank Research: India´s pharmaceutical industry on course for globalisation April 2008, www.dbresearch .com …for German Companies!?
Consequences India is a huge and promising market, but… compared to Germany: • different volume • different pricing levels • different spending per capita • different structure (directly payed by customer vs. health insurance) • different distribution systems • similar company structure (small to medium sized, privately owned) …more differences than similarities!
Chances / Challenges • for specialty care products, which are not yet available in India • which are patent protected or protected otherwise (production technologies) - Roundabout 20 German companies have established a presence in India • needs very careful analysis of the Indian markets • local partners which know the situation in India • marketing, reimbursement, distribution, authorities,
Market Access - Challenges • to obtain valid information for market evaluation / planning • to obtain sustainable information about government plans to develop the health system – mid to long term • to find partners in India • product protection by patents • Infrastructure • payment transactions • different time frames • high customs for imported goods • cultural challenges
Networking in the German Pharmaceutical IndustryHow to Use an Existing PlatformBPI - The German Pharmaceutical Industry Association - Established in 1951 -
The German Pharmaceutical Industry Association (BPI) • Established in 1951, with 57 years of experience in the development, regulatory approval and marketing of pharmaceuticals as well as political lobbying • An alliance of about 260 members, representing a wide spectrum of the pharmaceutical industry • Small Enterprises • Multinational Corporations • Contract Manufacturers • Contract Research Organizations (CROs) • Attorneys specializing in pharmaceutical law • Consultants • An ideal information and communication platform
The Staff of the BPI • The BPI covers many diverse fields of activities, which can be summarized in sixcentral core competencies: • Medicine and Pharmacy • Biotechnology / R & D • Politics • Law • Self Medication • Press / Public Relations • At BPI, experts from various disciplines work closely together – pharmacists, physicians, economists, lawyers, etc.
Support / BPI Cooperation platform The BPI Cooperation Platformon the BPI homepage offers • Members and • Non-members the opportunity to find business partners in various fields or to actively offer themselves as partners. Offers are posted anonymously, with the BPI acting as a intermediary between the two partners Might be useful to overcome some of the access barriers mentioned
Thank you for your attention! ngerbsch@bpi.de